By Fineline Cube 
Hangzhou-based cancer immunotherapy specialist iMBIORAY has received approval from China’s National Medical Products Administration (NMPA) to conduct a Phase II clinical study of its IBR854 in combination with pazopanib for advanced renal cell carcinoma (RCC). This marks a significant step forward in the development of this innovative therapy.
IBR854: First Non-Viral, Non-Genetically Modified CAR-NK Cell Therapy
IBR854, an in-house developed conjugated antibody redirecting ready-to-use allogeneic NK cells (CAR-raNK) product, is composed of a 5T4 antibody and NK cells. It represents the first non-viral vector, non-genetically modified CAR-NK cell immunotherapy for solid tumors in China. The 5T4 antigen, a highly glycosylated protein found on the cell surface, is widely distributed in various malignant tumors.
Clinical Progress and Safety Profile
The Phase I clinical study results demonstrated that IBR854 has good safety and tolerability. Building on these findings, the Phase II study will further evaluate the efficacy and safety of IBR854 in combination with pazopanib for the treatment of advanced RCC.-Fineline Info & Tech